Skip to main content

Table 1 Rheumatoid arthritis characteristics at baseline

From: Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

  First TNF antagonist monotherapy First TNF antagonist plus one csDMARD First TNF antagonist plus two or more csDMARDs Total P*
n, % 234 21 766 67 136 12 1.136 100  
Gender, female n, % 175 75 557 73 99 73 831 73 0.8
Rheumatoid factor (RF)+ n, % 183 78 619 81 104 77 906 80 0.4
ACPA + n, % * 47/71 66 330/431 77 47/70 67 424/ 572 74 0.06
RF- and ACPA- n, % 12 5 64 8 14 10 90 8 0.07
Erosions n, % 195 83 622 81 100 74 917 81 0.05
Rheumatoid nodules n, % 50 21 189 25 18 13 257 23 0.01
Joint arthroplasty n, % 15 6 66 9 3 2 84 7 0.02
Number of comorbidities n, %
 0 67 30 159 22 51 42 277 26 0.003
 1 32 14 72 10 12 10 116 11
 ≥2 124 56 481 68 57 48 662 63
Anti-hepatitis B antibody+ n, % 2/47 4 7/194 4 0/26 0 9/267 3 0.2
Anti-hepatitis C antibody+ n, % 6/46 13 6/195 3 2/26 8 14/267 5 0.05
PPD skin reaction + (≥5 mm) n, % 24 10 120 16 17 13 161/1.112 14 0.09
Secondary Sjögren’s syndrome n, % 44 19 128 17 17 12 189 17 0.2
Interstitial lung disease n, % 16 7 25 3 1 0.7 42 4 0.007
Recurrent infections n, % 5 2 11 1 1 0.7 17 2 0.54
Past cancer n, % 4 2 5 0.6 0 0 9 0.8 0.1
Mean ± SD          
Age (years) mean ± SD 55.9 ±13.7 52.8 ±13.4 50 .7 ±11.1 53.2 ±13.3 0.0001
Duration of disease (years) mean ± SD 9.4 ±8.0 9.0 ±7.5 8.8 ±7.3 9.1 ±7.6 0.8
Number of comorbidities mean ± SD 2.2 ±2.3 2.7 ±2.4 1.9 ±2.3 2.5 ±2.4 0.0001
Tender joint count (0–28) mean ± SD 10.9 ±6.4 10.3 ±6.6 11.6 ±6.9 10.6 ±6.6 0.0003
Swollen joint count (0–28) mean ± SD 9.0 ±6.1 7.9 ±5.5 8.5 ±5.8 8.2 ±5.7 0.02
Pain visual analogue scale (0–100) mean ± SD 61.9 ±19.3 63.5 ±22.2 66.0 ±20.8 63.4 ±21.5 0.01
DAS28-ESR mean ± SD 5.9 ±1.0 5.7 ±1.1 5.7 ±1.0 5.8 ±1.1 0.03
HAQ score (0–3) mean ± SD 1.40 ±0.58 1.44 ±0.65 1.6 ±0.59 1.46 ±0.63 0.0003
ESR (mm) mean ± SD 45.7 ±24.7 42.1 ±25.8 32.7 ±21.5 41.8 ±25.3 0.0001
C-reactive protein (mg/L) mean ± SD 19.3 ±21.4 15.7 ±21.5 15.8 ±19.4 16.5 ±21.2 0.0001
  1. csDMARD conventional synthetic disease-modifying antirheumatic drug, ACPA anti-citrullianted protein antibodies, PPD purified protein derivative skin reaction, DAS28-ESR disease activity score in 28 joints-erythrocyte sedimentation rate, HAQ health assessment questionnaire.
  2. *This variable was not assessed in all patients